# Aera Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/aera-therapeutics

- Industry: Biotechnology
- Headquarters: Boston, US
- Website: www.aeratx.com
- Latest round: Series B (Feb 16, 2023)
- Investors on record: 3

## About

Based in Boston, US, and founded in 2021 by Akin Akinc (CEO), John Maraganore, Robert Nelsen, Issi Rozen, Vicki Sato, David Schenkein, and Josh Wolfe, Aera Therapeutics Inc. is a biotechnology company that uses its proprietary technology to help deliver genetic medicines to various tissues and applications, thereby benefiting more patients across a wider range of disease areas. Aera Therapeutics Inc. is a biotechnology company that uses its proprietary technology to help deliver genetic medicines to various tissues and applications, thereby benefiting more patients across a wider range of disease areas. In February 2023, Aera Therapeutics Inc. raised Series B funding co-led by new investors ARCH Venture Partners, GV, and Lux Capital.

The company uses its proprietary protein nanoparticle (PNP) delivery platform, which leverages the discovery of endogenous, human proteins that can self-assemble into capsid-like structures and package and transfer nucleic acid cargo to enable various genetic medicine modalities. Moreover, the firm also offers a proprietary therapeutic enzyme platform based on the discovery of novel, compact, and programmable gene-editing enzymes.

## Funding rounds

- Series B, Feb 16, 2023 — ARCH Venture Partners, Lux Capital, GV
- Series A, Oct 22, 2022 — ARCH Venture Partners, GV

## Investors

- ARCH Venture Partners (https://capitalatlas.ai/funds/arch-venture-partners) — Series A, Series B
- GV (https://capitalatlas.ai/funds/gv) — Series A, Series B
- Lux Capital (https://capitalatlas.ai/funds/lux-capital) — Series B